BridgeBio Pharma vs Kiniksa Pharmaceuticals International
BBIO and KNSA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BBIO and KNSA compare
BridgeBio Pharma and Kiniksa Pharmaceuticals International are about the same size, with market caps of $15.3B and $15.1B.
BridgeBio Pharma grew revenue faster over the last twelve months (167% versus 58.2% for Kiniksa Pharmaceuticals International).
Kiniksa Pharmaceuticals International scores higher on the StockData Score (14 against 3 for BridgeBio Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BBIO | KNSA |
|---|---|---|
| Size and price | ||
| Market cap | $15.3B | $15.1B |
| Share price | $78.30 | $96.33 |
| Change, 1 year | 18.2% | 137% |
| Change, 5 years | 83.6% | 690% |
| Beta (5Y) | 1.11 | 0.31 |
| Employees | 834 | 366 |
| StockData Score | ||
| Total score | 3 | 14 (better) |
| Valuation score | 0 | 0 |
| Growth score | 2 | 4 (better) |
| Performance score | 0 | 4 (better) |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 74.1× |
| P/S | 16.1× | 16.0× (better) |
| P/B | – | 21.3× |
| EV/EBITDA | – | 110× |
| P/FCF | – | 76.8× |
| FCF yield | −2.4% | 1.3% (better) |
| Fair value | – | $17.17 |
| Margin of safety | – | −461% |
| Growth | ||
| Revenue growth (TTM) | 167% (better) | 58.2% |
| Revenue growth, 5Y average | 127% | – |
| Net income growth (TTM) | – | 205% |
| EPS growth (TTM) | – | 189% |
| Profitability | ||
| Gross margin | 94.3% (better) | 90.2% |
| Operating margin | −38.5% | 13.8% (better) |
| Net margin | – | 11.6% |
| FCF margin | −39.1% | 20.8% (better) |
| Return on equity | – | 17.6% |
| Return on invested capital | – | 60.2% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −7.1× | – |
| Current ratio | 2.09 | 3.91 (better) |
| Altman Z-score | 0.16 | 34.82 (better) |
| Piotroski F-score | – | 8 |
| Dividends and buybacks | ||
| Buyback yield | 1.7% | – |
| Shareholder yield | 1.7% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 99.4% | 29.9% |
| Held by insiders | 35.6% | 5.1% |
| Insider net buying, 12 months | −$84.8M (better) | −$122M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 16.6% | 2.9% |
Go deeper
- BBIO stock overview
- BBIO income statement
- BBIO valuation and score
- KNSA stock overview
- KNSA income statement
- KNSA valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.